---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-092350"
form_type: "8-K"
ticker: "AKTX"
cik: "0001541157"
company_name: "Akari Therapeutics Plc"
filed_at: "2025-07-01T23:59:59+00:00"
generated_at: "2026-05-18T09:58:49.826221+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Akari shareholder-approved 11B share increase for equity plan and director option grant of 1.35M ADSs

## Summary
- Shareholders approved increase in 2023 Plan share pool by 11,026,000,000 ordinary shares (5,513,000 ADSs) to 19,806,000,000 ordinary shares.
- Approved aggregate time-vested option grant of 1,350,000 ADSs (2.7B ordinary shares) to six directors, representing 4.2% of issued share capital.
- Re-elected all six director nominees: Hoyoung Huh, Robert Bazemore, James Neal, Sandip Patel, Samir Patel, Abizer Gaslightwala.
- Ratified BDO USA as independent auditor for FY2025 and HaysMac as statutory auditor.
- Advisory votes on NEO compensation and board remuneration report passed.

## SEC filing metadata
- accession: 0000950170-25-092350
- form_type: 8-K
- ticker: AKTX
- cik: 0001541157
- company_name: Akari Therapeutics Plc
- filed_at: 2025-07-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1541157/000095017025092350/0000950170-25-092350-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1541157/000095017025092350/aktx-20250630.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-092350
- JSON: https://secwatch.observer/filing/0000950170-25-092350.json
- Plain text: https://secwatch.observer/filing/0000950170-25-092350.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.